Acadia Pharmaceuticals Inc (ACAD) Options

ACAD at a bottom

Adding $$$$$

We added

More science on the way folks

Time to buy more

Been in

Good time to add or get in today!

Good time to add to the stash $$$$

Been in here a long time.

Off and on since the $1 range

Let’s go

You will soon enough

Boom

Acadia Pharmaceuticals surges 32% after win in patent suit over Nuplazid

Dec 13, 2023 10:15 AM ET | ACADIA Pharmaceuticals Inc. (ACAD) | Joshua Fineman, SA News Editor

Acadia Pharmaceuticals (NASDAQ:ACAD) jumped 32% after winning summary judgement in a patent suit regarding its drug Nuplazid, which is used to treat Parkinson's disease. Acadia won the judgement against generic maker MSN Laboratories.
"For the foregoing reasons, the Court grants summary judgement to Acadia," U.S. Disctrict Court Judge Gregory B. Williams wrote in a court opinion on Wednesday.
Acadia (ACAD) filed separate lawsuits last October alleging that copies of Nuplazid infringed a patent, including a lawsuit against MSN Laboratories

I should live so long

Oh it’l happen, enough said

Harry, I haven’t seen any buyout rumours for Acadia since March 2015. What are you talking about or hoping for?

Please provide a link.

27k shares waiting on the buyout news! Happy early retirement all over again
$$$$$$

Boom

Keeps going up here

ACAD new 52 week high

Boom

Shares of Acadia climbed 17% in after-hours trading Thursday.

Price: 30.25, Change: +4.45, Percent Change: +17.25



ACADIA Pharmaceuticals Acquires Ex-North America Rights to Trofinetide, Global Rights to NNZ-2591; Shares Rise After Hours
2023-07-13 05:26:11 PM ET (MT Newswires)


05:26 PM EDT, 07/13/2023 (MT Newswires) -- ACADIA Pharmaceuticals (ACAD) said Thursday it expanded its current licensing agreement for trofinetide, a treatment for Rett syndrome, with Neuren Pharmaceuticals to acquire ex-North American rights to the drug.

The agreement also gives Acadia global rights to Neuren's NNZ-2591 in Rett syndrome and Fragile X syndrome.

Under the agreement, Neuren will receive an upfront payment of $100 million and may receive potential downstream milestone and royalty payments earned separately for trofinetide and NNZ-2591.

Outside of North America, Neuren may receive additional payments for trofinetide upon the achievement of certain revenue milestones and it will also get tiered royalties from the mid-teens to low-twenties percent of trofinetide sales.

Potential future payments to Neuren related to NNZ-2591 in Rett syndrome and Fragile X syndrome are equal to the payments for trofinetide in each of North America and outside North America, Acadia said.

Acadia said it plans to submit a new drug submission for trofinetide in Canada in the next 18 months. It will announce plans for Europe, Asia and other regions at a later date.

Shares of Acadia climbed 17% in after-hours trading Thursday.

Price: 30.25, Change: +4.45, Percent Change: +17.25

Beautiful day $$$$

Is Martin Shkreli in charge of Acadia, or some other cold psycho-bstrd? Shkreli was released to a half way house in May of last year.

https://www.cnbc.com/2022/05/18/martin-shkreli-released-from-federal-prison-into-halfway-house-.html#:~:text=Shkreli%20was%20arrested%20in%20late,that%20he%20had%20covered%20up.

https://www.marketwatch.com/story/acadias-rare-disease-drug-to-cost-575-000-to-595-000-5e883843

https://news.sky.com/story/martin-shkreli-man-who-made-huge-profits-by-inflating-price-of-life-saving-drug-ordered-to-return-47m-12516161#:~:text=Data%20%26%20Forensics-,Martin%20Shkreli%3A%20Man%20who%20made%20huge%20profits%20by%20inflating%20price,rights%20to%20it%20in%202015.

30’s coming folks, patience

ACAD hopefully Opening will give a boost but I just got out with a meager profit, not appreciating P-M action. I'm playing for a batting average this year and keep my distance from red. GL!

If the price is right, yes

Or dumb for not selling when it was in the upper $50's years ago. ;)

Phew, $2.1>. Nice!
You are patient..

Mine are at $2.18.....been holding for a looong time. Hope we can get back into the upper $50's and maybe beyond.

Do you think anyone would want to do a buyout?

ACAD...... APPROVED!

Strong ticker

Still hold shares at 5.00 here

Nice day for acad holders??

$ACAD is covered by 10 analysts:

Sell zero
Neutral seven
Buy three

RBC Boosts Price Target on ACADIA Pharmaceuticals to $27 From $19, Maintains Outperform Rating
2023-02-28 08:14:38 AM ET (MT Newswires)


08:14 AM EST, 02/28/2023 (MT Newswires) -- ACADIA Pharmaceuticals (ACAD) has an average investment rating of hold among analysts polled by Capital IQ, with price targets ranging from $10 to $28.

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www.mtnewswires.com/contact-us)

Throughout market turmoil thanks to biden an his brainless entourage acad holding up well in portfolio’s $$$$

1 an 3 month chart are winners for those who added! $$$$

Lmao shorty, the BB’s are far more advanced than you, i kno them well, GL an in the trading world there is a word spelled c o v e r, If i were you i would look up what it means. Enough said, happy trading folks, patience…. $$$$

An ironic twist of fate.
The law of unintended consequences.
Most of you are overly invested in Acadia pharma.
Most of you are deep underwater with your investment.
Most of you have averaged down and even taken out a 2nd mortgage to do so.
Most of you are hoping that Trofinetide will be FDA approved for RETT syndrome on March 12th, 2023.
Most of you think Acadia's share price will rise upon FDA approval.
Most of you are just hoping to break even to bail out of this Titanic boat anchor.
Most of you don't realize that the stock price will dive upon Trofinetide approval.
It costs more to manufacture and sell Trofinetide, than full sales could ever pay for let alone make a profit.
The same is true of Nuplazid, it costs more to manufacture and sell, than any meager "profits" can bring in.
The Baker Brothers only own Acadia pharma stock, as a tax write-off...
Every hedge fund, needs one bad apple in the bunch, just to offset taxes on the other, profitable holdings.
Criss-Cross, you bet the wrong dog!

The volume today has been only the selling of shares, back into the public float/pool, no one is buying shares, hence the downward pressure on the stock price. It's simply not true that for every seller, there is a buyer, there are many shares still in the public float that Acadia owns, to sell into the market, for their own financial gain, when and if those shares are purchased. When a person buys a stock out of the public float pool, that money goes directly into Acadia's pockets...

Pretty standard stuff.
Most Pharma companies have legal issues like this.

None of this will move the needle in either direction IMHO

OK, that's good but what about this?
https://www.lawow.org/karp-vs-acadia-pharmaceuticals-inc-2021-11-22/
2 people died because Acadia illegally hired a convicted felon as a pharma sales, rep that sold them fentanyl. Unlimited damages and liabilities. Why would Acadia hire a felon? Why does Stephen Davis have his shirt unbuttoned down so far during conference calls?

Uh Oh! what about this lawsuit??? Hmmm...????

NEW ORLEANS, Nov. 11, 2022 /PRNewswire/ -- Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC ("KSF"), announces that KSF has commenced an investigation into ACADIA Pharmaceuticals Inc. (NasdaqGS: ACAD).

On July 20, 2020, the Company announced that the FDA had accepted for filing its supplemental new drug application ("sNDA") for its drug candidate, pimavanserin, for the treatment of dementia-related psychosis ("DRP"). Thereafter, the company repeatedly stated the FDA had not identified any potential review issues and reiterated the drug's efficacy. Then, on April 5, 2021, the Company disclosed that the FDA had rejected the sNDA, citing a lack of statistical significance regarding some of the subgroups of dementia and inadequate numbers of patients with some less common dementia subtypes.

ACAD is the plaintiff and filed suit due to patent infringement claims.

This is pretty standard stuff and actually good for ACAD that their patent attorneys are going after folks trying to jump their patents.

Wow, yet another lawsuit!

https://casetext.com/case/acadia-pharm-v-aurobindo-pharma

Uh oh, Acadia going out of business due to 2 wrongful death lawsuits, with unlimited damages.

https://www.lawow.org/karp-vs-acadia-pharmaceuticals-inc-2021-11-22/

Good pop today

Things like that happen with bio’s, it’’s still a promising company to invest in, theres other drug science capable of moving forward just like any other. those who followed us from the beginning of acad, at 2-5$ a share made a ton of wealth over the years whether they flipped in or out at variable times was their choice, its called trading, making wealth. To invest 25k at 3$ pps and to sell at 50 pps is a very large gain of wealth my friend. Those who didn’t sell well don’t blame acad for that. You think the BB’s invested not to sell? Ah, no they sure didn’t. We hold a chunk of acad yet but that is all free shares, no matter what price it goes to. As for other stocks you mentioned, it’s the same, wealth made an just sitting on free shares, who really cares what happens once your initial investment is paid for in gains. GL to you an never be greedy, take profits as u wish

What about the latest shelf offering and the lowered guidance? Do you enjoy it?

Ah listen pal, before u make a comment you should know what exactly your commenting on! Acad has made investors millions of dollars since the beginning stages of its first trial an first nda! I guess you do not know this, over the years investing in this company has been nothing but positive an for someone like you to comment on an issue you have no clue about is absurd! Get lost an go crawl under a rock

Big mistake listening to Harry Crumb! Keep in mind that he invested in a used car salesman owned scam with with water less tooth brushes and paper less toilet paper.

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Company has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding its supplemental New Drug Application (sNDA) for NUPLAZID(R) (pimavanserin) for the treatment of hallucinations and delusions associated with Alzheimer's disease psychosis (ADP).

The CRL indicated that the FDA has completed review of the application, determining that it could not approve the sNDA in its present form, and recommended that Acadia conduct an additional trial in ADP. While the FDA stated that Study 019 demonstrated a statistically significant treatment effect on its primary endpoint, they concluded that there are limitations in the interpretability of the 019 results. The FDA also stated that the positive treatment effect of pimavanserin on dementia-related psychosis in Study 045 (HARMONY) appeared to be driven by the robustly positive results in the Parkinson's disease dementia subgroup, a condition they stated is subsumed within the currently approved NUPLAZID Parkinson's disease psychosis (PDP) indication. Up to 50 percent of PDP patients have dementia.(1)

"We are disappointed with this outcome. The treatment of Alzheimer's disease psychosis continues to be an area of high unmet need, for which there is no approved therapy," said Steve Davis, Chief Executive Officer. "We want to express our gratitude to all of the patients, their families and investigators who have participated in our clinical trials."

NUPLAZID was approved in the U.S. in 2016 and is the first and only treatment for hallucinations and delusions associated with PDP.